Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors

Laura Newell, KELSEA M. SHOOP, REBEKAH J. KNIGHT, SARA N. MURRAY, ROGELYN P. KWOCK, CAROL E. JACOBY, Susan Slater, BRYON E. ALLEN, CASONDRA OTTOWA, B. R.A.D. COTA, PEGGY L. APPEL, RACHEL J. COOK, Richard Maziarz, Gabrielle Meyers

Research output: Contribution to journalArticle

Abstract

Background: Guidelines recommend treatment with 4–5 days of granulocyte colony-stimulating factor (G-CSF)for optimal donor peripheral blood progenitor cell (PBPC)mobilization followed by day 5 collection. Given that some autologous transplant recipients achieve adequate collection by day 4 and the possibility that some allogeneic donors may maximally mobilize PBPC before day 5, a feasibility study was performed evaluating day 4 allogeneic PBPC collection. Methods: HLA-matched sibling donors underwent collection on day 4 of G-CSF for peripheral blood (PB)CD34 + counts ≥0.04 × 10 6 /mL, otherwise they underwent collection on day 5. Those with inadequate collected CD34 + cells/kg recipient weight underwent repeat collection over 2 days. Transplant and PBPC characteristics and cost analysis were compared with a historical cohort collected on day 5 per our prior institutional algorithm. Results: Of the 101 patient/donor pairs, 50 (49.5%)had adequate PBPC collection on day 4, with a median PB CD34 + cell count of 0.06 × 10 6 /mL. Day 4 donors were more likely to develop bone pain and require analgesics. Median collected CD34 + count was significantly greater, whereas total nucleated, mononuclear and CD3 + cell counts were significantly lower, at time of transplant infusion for day 4 versus other collection cohorts. There were no significant differences in engraftment or graft-versus-host disease. Cost analysis revealed 6.7% direct cost savings for day 4 versus historical day 5 collection. Discussion: Day 4 PB CD34 + threshold of ≥0.04 × 10 6 /mL identified donors with high likelihood of adequate PBPC collection. Day 4 may be the optimal day of collection for healthy donors, without adverse effect on recipient transplant outcomes and with expected cost savings.

Original languageEnglish (US)
JournalCytotherapy
DOIs
StatePublished - Jan 1 2019

Fingerprint

Granulocyte Colony-Stimulating Factor
Siblings
Blood Cells
Stem Cells
Tissue Donors
Costs and Cost Analysis
Cost Savings
Transplants
Blood Cell Count
Autografts
Feasibility Studies
Graft vs Host Disease
Analgesics
Cell Count
Guidelines
Weights and Measures
Bone and Bones
Pain

Keywords

  • hematopoietic progenitor cells
  • hematopoietic stem cell transplantation
  • peripheral blood stem cells
  • stem cell mobilization

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Transplantation
  • Cancer Research

Cite this

Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors. / Newell, Laura; SHOOP, KELSEA M.; KNIGHT, REBEKAH J.; MURRAY, SARA N.; KWOCK, ROGELYN P.; JACOBY, CAROL E.; Slater, Susan; ALLEN, BRYON E.; OTTOWA, CASONDRA; COTA, B. R.A.D.; APPEL, PEGGY L.; COOK, RACHEL J.; Maziarz, Richard; Meyers, Gabrielle.

In: Cytotherapy, 01.01.2019.

Research output: Contribution to journalArticle

Newell, Laura ; SHOOP, KELSEA M. ; KNIGHT, REBEKAH J. ; MURRAY, SARA N. ; KWOCK, ROGELYN P. ; JACOBY, CAROL E. ; Slater, Susan ; ALLEN, BRYON E. ; OTTOWA, CASONDRA ; COTA, B. R.A.D. ; APPEL, PEGGY L. ; COOK, RACHEL J. ; Maziarz, Richard ; Meyers, Gabrielle. / Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors. In: Cytotherapy. 2019.
@article{55f7a26c250c46d69794384c26d27a2f,
title = "Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors",
abstract = "Background: Guidelines recommend treatment with 4–5 days of granulocyte colony-stimulating factor (G-CSF)for optimal donor peripheral blood progenitor cell (PBPC)mobilization followed by day 5 collection. Given that some autologous transplant recipients achieve adequate collection by day 4 and the possibility that some allogeneic donors may maximally mobilize PBPC before day 5, a feasibility study was performed evaluating day 4 allogeneic PBPC collection. Methods: HLA-matched sibling donors underwent collection on day 4 of G-CSF for peripheral blood (PB)CD34 + counts ≥0.04 × 10 6 /mL, otherwise they underwent collection on day 5. Those with inadequate collected CD34 + cells/kg recipient weight underwent repeat collection over 2 days. Transplant and PBPC characteristics and cost analysis were compared with a historical cohort collected on day 5 per our prior institutional algorithm. Results: Of the 101 patient/donor pairs, 50 (49.5{\%})had adequate PBPC collection on day 4, with a median PB CD34 + cell count of 0.06 × 10 6 /mL. Day 4 donors were more likely to develop bone pain and require analgesics. Median collected CD34 + count was significantly greater, whereas total nucleated, mononuclear and CD3 + cell counts were significantly lower, at time of transplant infusion for day 4 versus other collection cohorts. There were no significant differences in engraftment or graft-versus-host disease. Cost analysis revealed 6.7{\%} direct cost savings for day 4 versus historical day 5 collection. Discussion: Day 4 PB CD34 + threshold of ≥0.04 × 10 6 /mL identified donors with high likelihood of adequate PBPC collection. Day 4 may be the optimal day of collection for healthy donors, without adverse effect on recipient transplant outcomes and with expected cost savings.",
keywords = "hematopoietic progenitor cells, hematopoietic stem cell transplantation, peripheral blood stem cells, stem cell mobilization",
author = "Laura Newell and SHOOP, {KELSEA M.} and KNIGHT, {REBEKAH J.} and MURRAY, {SARA N.} and KWOCK, {ROGELYN P.} and JACOBY, {CAROL E.} and Susan Slater and ALLEN, {BRYON E.} and CASONDRA OTTOWA and COTA, {B. R.A.D.} and APPEL, {PEGGY L.} and COOK, {RACHEL J.} and Richard Maziarz and Gabrielle Meyers",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jcyt.2019.04.001",
language = "English (US)",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors

AU - Newell, Laura

AU - SHOOP, KELSEA M.

AU - KNIGHT, REBEKAH J.

AU - MURRAY, SARA N.

AU - KWOCK, ROGELYN P.

AU - JACOBY, CAROL E.

AU - Slater, Susan

AU - ALLEN, BRYON E.

AU - OTTOWA, CASONDRA

AU - COTA, B. R.A.D.

AU - APPEL, PEGGY L.

AU - COOK, RACHEL J.

AU - Maziarz, Richard

AU - Meyers, Gabrielle

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Guidelines recommend treatment with 4–5 days of granulocyte colony-stimulating factor (G-CSF)for optimal donor peripheral blood progenitor cell (PBPC)mobilization followed by day 5 collection. Given that some autologous transplant recipients achieve adequate collection by day 4 and the possibility that some allogeneic donors may maximally mobilize PBPC before day 5, a feasibility study was performed evaluating day 4 allogeneic PBPC collection. Methods: HLA-matched sibling donors underwent collection on day 4 of G-CSF for peripheral blood (PB)CD34 + counts ≥0.04 × 10 6 /mL, otherwise they underwent collection on day 5. Those with inadequate collected CD34 + cells/kg recipient weight underwent repeat collection over 2 days. Transplant and PBPC characteristics and cost analysis were compared with a historical cohort collected on day 5 per our prior institutional algorithm. Results: Of the 101 patient/donor pairs, 50 (49.5%)had adequate PBPC collection on day 4, with a median PB CD34 + cell count of 0.06 × 10 6 /mL. Day 4 donors were more likely to develop bone pain and require analgesics. Median collected CD34 + count was significantly greater, whereas total nucleated, mononuclear and CD3 + cell counts were significantly lower, at time of transplant infusion for day 4 versus other collection cohorts. There were no significant differences in engraftment or graft-versus-host disease. Cost analysis revealed 6.7% direct cost savings for day 4 versus historical day 5 collection. Discussion: Day 4 PB CD34 + threshold of ≥0.04 × 10 6 /mL identified donors with high likelihood of adequate PBPC collection. Day 4 may be the optimal day of collection for healthy donors, without adverse effect on recipient transplant outcomes and with expected cost savings.

AB - Background: Guidelines recommend treatment with 4–5 days of granulocyte colony-stimulating factor (G-CSF)for optimal donor peripheral blood progenitor cell (PBPC)mobilization followed by day 5 collection. Given that some autologous transplant recipients achieve adequate collection by day 4 and the possibility that some allogeneic donors may maximally mobilize PBPC before day 5, a feasibility study was performed evaluating day 4 allogeneic PBPC collection. Methods: HLA-matched sibling donors underwent collection on day 4 of G-CSF for peripheral blood (PB)CD34 + counts ≥0.04 × 10 6 /mL, otherwise they underwent collection on day 5. Those with inadequate collected CD34 + cells/kg recipient weight underwent repeat collection over 2 days. Transplant and PBPC characteristics and cost analysis were compared with a historical cohort collected on day 5 per our prior institutional algorithm. Results: Of the 101 patient/donor pairs, 50 (49.5%)had adequate PBPC collection on day 4, with a median PB CD34 + cell count of 0.06 × 10 6 /mL. Day 4 donors were more likely to develop bone pain and require analgesics. Median collected CD34 + count was significantly greater, whereas total nucleated, mononuclear and CD3 + cell counts were significantly lower, at time of transplant infusion for day 4 versus other collection cohorts. There were no significant differences in engraftment or graft-versus-host disease. Cost analysis revealed 6.7% direct cost savings for day 4 versus historical day 5 collection. Discussion: Day 4 PB CD34 + threshold of ≥0.04 × 10 6 /mL identified donors with high likelihood of adequate PBPC collection. Day 4 may be the optimal day of collection for healthy donors, without adverse effect on recipient transplant outcomes and with expected cost savings.

KW - hematopoietic progenitor cells

KW - hematopoietic stem cell transplantation

KW - peripheral blood stem cells

KW - stem cell mobilization

UR - http://www.scopus.com/inward/record.url?scp=85065408195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065408195&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2019.04.001

DO - 10.1016/j.jcyt.2019.04.001

M3 - Article

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

ER -